Maria Giuseppa Sarobba

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Emilio Bajetta, Irene Floriani, Maria Di Bartolomeo et al. · Annals of Oncology · 2014 · 90 citations · Full text

Medicine, Oncology, Chemotherapy +10

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design

Alfredo Berruti, Raffaella Bitossi, G. Gorzegno et al. · Journal of Clinical Oncology · 2002 · 83 citations

Medicine, Oncology, Pharmacology +16

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Marina Elena Cazzaniga, G. Pinotti, Emilia Montagna et al. · The Breast · 2019 · 57 citations

Medicine, Oncology, Breast Oncology +9

TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.

Marina Chiara Garassino, Olga Martelli, Anna Bettini et al. · Journal of Clinical Oncology · 2012 · 54 citations

Pharmacy, Oncology, Pharmacotherapy +11